Magazine Article | January 2, 2019

Companies To Watch: Synspira

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Fighting lung infection, inflammation, and congestion in the new glycomics space.

Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. The inhaled drugs are designed to enhance or restore the protective, antimicrobial properties of the glycocalyx, a layer of sugar molecules coating cells, an important constituent of mucus, and the first defensive barrier of innate immunity. When the glycocalyx is damaged or disrupted, harmful bacteria thrive and form obstructive biofilms involved in multiple maladies. The company’s products appear to help kill bacteria, break up the biofilm for the lungs to expel, and thereby increase antibiotic effectiveness.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: